New Treatment Options to Overcome Challenges in Hemophilia A Management With Regina Butler, RN-BC and Michael Callaghan, MD

In this podcast, expert clinicians review strategies to engage patients with hemophilia A in their own care to improve overall patient satisfaction.

In this podcast, a clinician and patient discuss his experience with hemophilia A, addressing patient concerns regarding this condition, its management, and preferred communication methods. 

In this podcast, expert clinicians discuss recent and emerging treatment options with the potential to benefit patients with and without inhibitors.

In this podcast, expert clinicians discuss historical challenges in hemophilia A care and how recent therapeutic advancements help to overcome these limitations. 

Hemophilia A is an X-linked recessive disease primarily affecting males. An estimated 20,000 individuals in the United States have the disease. Conventional standard of care for patients with severe disease is factor VIII administration given prophylactically or to treat bleeding episodes. Almost 30% of patients treated with factor VIII develop neutralizing antibodies known as inhibitors, which require treatment with expensive bypassing agents. Newer approaches to treating hemophilia A include pegylated recombinant factor VIII agents with a longer half-life that allow for reduced dosing, as well as emicizumab, a bispecific antibody therapy that mimics the cofactor activity of factor VIII by binding to and bridging activated factor IX and factor X. In this 4-part CME podcast series, experts will summarize historical challenges in hemophilia A care; discuss how newer treatment options may benefit patients with and without inhibitors; and present strategies to promote shared decision-making and improve patient satisfaction. Additionally, faculty will speak with a patient advocate regarding treatment concerns and communication preferences.